(NASDAQ:ORIC), SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that a preclinical abstract highlighting the potential of ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat […]

(NasdaqGM:TNGX), BOSTON, March 25, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30,

(NasdaqGM:NRIX), SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that company scientists will present preclinical data from its proprietary DEL-AI platform and several degrader programs in two oral presentations and two poster

Multiple presentations demonstrate that T-knife's proprietary next-generation technologies address important challenges with current cell therapy constructs, including boosting T cell fitness and persistence within an immunosuppressive tumor microenvironment TK-6302, a supercharged PRAME T cell therapy, is rapidly advancing towards a Clinical Trial Application (CTA) filing in the fourth quarter of 2025 SAN FRANCISCO and BERLIN,

(NasdaqGM:AFMD), MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the risk of developing cancer, especially colorectal and endometrial cancers NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer before tumors develop Full safety and immunogenicity results from a Phase Ib/II study of NOUS-209

Conference call will be held on March 26, 2025 at 11AM ET Zoomd Technologies Ltd.(TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, “Zoomd” or the “Company”), the marketing technology (MarTech) user-acquisition and engagement platform, today reported its financial results for the three months and full year periods ended December 31, 2024. The

AerCap Ireland Capital Designated Activity Company and AerCap Global Aviation Trust (together, the “Issuers”), each a wholly-owned subsidiary of AerCap Holdings N.V. (“AerCap” or the “Company”), priced an offering of $500 million aggregate principal amount of the Issuers' Fixed-Rate Reset Junior Subordinated Notes due 2056 (the “Notes”). The Notes will be issued with an initial

(NasdaqGM:GWRS), PHOENIX, March 25, 2025 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by the company. In addition, the company expects to grant the underwriters

(NasdaqGM:WRD), NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — WeRide Inc. (Nasdaq: WRD) (“WeRide” or the “Company”), a global leader in autonomous driving technology, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission (“SEC”) on March 25, 2025. The